Jeroen Hostens

Journal Article
A1
open access

Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies

Leander Huyghe (UGent) , Alexander Van Parys (UGent) , Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Stijn De Munter (UGent) , Jennyfer Bultinck (UGent) , Lennart Zabeau (UGent) , Jeroen Hostens, An Goethals, Nele Vanderroost (UGent) , et al.

(2020) EMBO MOLECULAR MEDICINE. 12(2).

Add to list

Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis

Ken Coppieters (UGent) , Torsten Dreier, Karen Silence, Hans de Haard, Marc Lauwereys, Peter Casteels, Els Beirnaert, Heidi Jonckheere, Christophe Van De Wiele (UGent) , Ludovicus Staelens, et al.

(2006) ARTHRITIS AND RHEUMATISM. 54(6). p.1856-1866

Add to list

Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics

Peter Brouckaert (UGent) , N TAKAHASHI, ST VAN TIEL, Jeroen Hostens, AMM EGGERMONT, ALB SEYNHAEVE, Walter Fiers and TLM TEN HAGEN

(2004) INTERNATIONAL JOURNAL OF CANCER. 109(3). p.442-448

Add to list

Bioavailability of recombinant tumor necrosis factor determines its lethality in mice.

Paul Ameloot (UGent) , Nozomi Takahashi (UGent) , Bart Everaerdt, Jeroen Hostens, HP EUGSTER, Walter Fiers and Peter Brouckaert (UGent)

(2002) EUROPEAN JOURNAL OF IMMUNOLOGY. 32(10). p.2759-2765

Academic Bibliography

Jeroen Hostens

Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies

Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis

Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics

Bioavailability of recombinant tumor necrosis factor determines its lethality in mice.

Contents

Support

Contact